Please join us for a five-part virtual series presented Wednesdays from 8:00-9:00 AM ET, hosted on an event platform that includes a dedicated “exhibit hall.” Each session includes two expert presentations followed by a Q&A with the presenters and a moderator.

The goal of the inaugural MAP series is to educate health care providers and team members, including industry partners, about the basics of genomics, understanding genomic reports including variants of unknown significance, and therapeutic application. Ultimately, we seek to accelerate the clinical development and clinical application of precision diagnostics and therapies for patients with cancer and to improve the outcomes for patients who are battling this difficult-to-treat disease.

Time: 8:00-9:00 AM ET

April 21, 2021
April 28, 2021
May 5, 2021
May 12, 2021
May 19, 2021


  • Pancancer analysis of whole genomes
  • Functional and genomic characterization of circulating tumor cells: a window into tumor biology and evolution
  • Genotyping techniques and reports
  • Germline and ethical considerations
  • Targeting ALK, ROS and other fusion drivers
  • Targeting the MET pathway
  • Targeting the PI3K pathway
  • Plasma vs tissue genotyping
  • Role of immunology in precision medicine
  • Role of antibody drug conjugates in precision medicine

Learning Objectives:

  • Identify the therapeutic strategies to target actionable oncogenic drivers in non-small cell lung cancer.
  • Appraise the various alterations in the PI3K and MAPK pathway and potential therapeutic strategies.
  • Review the role of tumor mutation burden and other tissue-agnostic biomarkers in mediating response to immunotherapy.
  • Examine the components of antibody drug-conjugates and therapeutic role in solid tumors.

Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians. Details about CME credit will be available via the registration link.

Register Here

For more information, please contact:
Karen Eldridge (; 919-475-0454) or
Melissa Cather (; 617-593-5588).